Shares of Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report) fell 8.2% during trading on Friday . The stock traded as low as $1.57 and last traded at $1.57. 5,935 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 268,050 shares. The stock had previously closed at $1.71.
Chromocell Therapeutics Price Performance
The company’s 50 day simple moving average is $1.77 and its 200 day simple moving average is $1.08.
Chromocell Therapeutics Company Profile
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
See Also
- Five stocks we like better than Chromocell Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- The Basics of Support and Resistance
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
